Synlogic stock.

Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ...Synlogic Announces Reverse Stock Split. September 27, 2023. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), ...Institutional investors have sold a total of 13,539,674 shares in the last 24 months. This volume of shares sold represents approximately $97.33M in transactions. Iterum Therapeutics Institutional Ownership. This page (NASDAQ:SYBX) was last updated on 11/16/2023 by MarketBeat.com Staff.The value each SYBX share was expected to gain vs. the value that each SYBX share actually gained.. Synlogic (SYBX) reported Q3 2023 earnings per share (EPS) of-$2.57, missing estimates of -$2.18 by 17.89%.In the same quarter last year, Synlogic's earnings per share (EPS) was-$3.73.Synlogic is expected to release next earnings on …SYBX Stock 12 Months Forecast. $21.67. (983.50% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Synlogic in the last 3 months. The average price target is $21.67 with a high forecast of $35.00 and a low forecast of $6.00. The average price target represents a 983.50% change from the last price of $2.00.

On average, Wall Street analysts predict. that Synlogic's share price could reach $82.50 by Aug 11, 2024. The average Synlogic stock price prediction forecasts a potential upside of 4,025% from the current SYBX share price of $2.00.Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Nov 9, 2023 · Synlogic is a biotechnology company that designs Synthetic Biotics, living probiotics that treat diseases with Synthetic Biotic pipeline. The web page provides stock quote, chart, news releases, events, and corporate documents of Synlogic, as well as investor resources and contact information.

٢٨‏/٠٨‏/٢٠١٧ ... New York Stock Exc... ... No photo description available. Bloomberg. 󱢏. Media ...Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Sep 22, 2021 · All shares of common stock to be sold in the offering are being sold by Synlogic. In addition, Synlogic has granted to the underwriter a 30-day option to purchase up to 2,250,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Analyst Keay Nakae of Chardan Capital reiterated a Buy rating on Synlogic (SYBX – Research Report), with a price target of $35.00. Keay Nakae’s Buy rating for Synlogic is rooted in several ...Based on short-term price targets offered by three analysts, the average price target for Synlogic, Inc. comes to $21.67. The forecasts range from a low of $6.00 to a high of $35.00. The average ...Synlogic Inc stock performance at a glance. Check Synlogic Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.

Dec 1, 2023 · Earnings Flash (SYBX) SYNLOGIC Posts Q3 Revenue $393,000. Nov. 09. MT. Synlogic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 09. CI. Synlogic, Inc. Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration. Nov. 07. CI.

Complete Synlogic Inc. stock information by Barron's. View real-time SYBX stock price and news, along with industry-best analysis.

Discover historical prices for SYBX stock on Yahoo Finance. View daily, weekly or monthly format back to when Synlogic, Inc. stock was issued. Over the past week, Wood has been accumulating shares of Verve Therapeutics (VERV-6.12%) for her firm's flagship growth stock fund, the ARK Innovation ETF (ARKK 0.43%), and the biotech-focused ARK ...The Investor Relations website contains information about Synlogic's business for stockholders, potential investors, and financial analysts.CAMBRIDGE, Mass., Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial.SYNB1891 is an investigational drug for the intra-tumoral treatment …Chardan Raises Price Target on Synlogic to $6 From $5.50 Reflecting Lower Cash Burns Due to Recent Downsizing, Keeps Buy Rating. Jun. 06. MT. SVB Securities Cuts Synlogic's Price Target to $4 From $8, Maintains Outperform Rating. May. 12. MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept.

CAMBRIDGE, Mass., Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial.SYNB1891 is an investigational drug for the intra-tumoral treatment …Mar 29, 2023 · CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ... Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options ...Figure 5: Synlogic Stock Chart (source: finviz) Thus, Synlogic looks like a good value at current levels, although, obviously, still a high-risk investment due to the early stages of its assets.So should Synlogic (NASDAQ:SYBX) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund ...About Synlogic Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat ...Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI

CAMBRIDGE, Mass., Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial.SYNB1891 is an investigational drug for the intra-tumoral treatment …Dec 15, 2022 · Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.

Chardan Raises Price Target on Synlogic to $6 From $5.50 Reflecting Lower Cash Burns Due to Recent Downsizing, Keeps Buy Rating. Jun. 06. MT. SVB Securities Cuts Synlogic's Price Target to $4 From $8, Maintains Outperform Rating. May. 12. MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept.Synlogic ( SYBX) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 9, 2023 for Q3 and the Actual Revenue was $393K, which beat the ...Interactive Chart for Synlogic, Inc. (SYBX), analyze all the data with a huge range of indicators. Synlogic, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...What is Synlogic's consensus rating and price target? According to the issued ratings of 2 analysts in the last year, the consensus rating for Synlogic stock is Buy based on the current 2 buy ratings for SYBX. The average twelve-month price prediction for Synlogic is $82.50 with a high price target of $90.00 and a low price target of $75.00.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...

٢٧‏/٠٩‏/٢٠٢٣ ... Synlogic (SYBX) Announces Reverse Stock Split ... Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Synlogic (SYBX – Research Report), with a price target of $24.00. Ed Arce has given his Buy rating due to a ...

Nov 9, 2023 · Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options ... The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Historical daily share price chart and data for Synlogic since 2015 adjusted for splits and dividends. The latest closing stock price for Synlogic as of November 27, 2023 is 1.97.. …Synlogic Inc stock performance at a glance. Check Synlogic Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. Ginkgo has purchased 6,340,771 shares of Synlogic common stock as well as pre-funded warrants to purchase up to 2,548,117 shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The transactions were executed and closed on June 11, 2019.Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candid ates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. The Company uses programmable, precision ...CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...Synlogic Inc stocks price quote with latest real-time prices, charts, financials, latest news, ... Do the numbers hold clues to what lies ahead for the stock? SYBX: 0.8376 (-3.60%) ROIV: 5.14 (-2.10%) Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks PR Newswire - Thu Aug 11, 6:05AM CDTThe company earned $0.39 million during the quarter, compared to analysts' expectations of $0.04 million. Synlogic has generated ($12.76) earnings per share over the last year (($12.76) diluted earnings per share). Earnings for Synlogic are expected to grow in the coming year, from ($6.25) to ($5.32) per share.

INMB stock currently trades for $7.80 and reached a 52-week high of $11.78 while carrying an average target stock price of $18.00. Synlogic (SYBX) Biotechnology stocks, biomedical stocks.View live Synlogic, Inc. chart to track its stock's price action. Find market predictions, SYBX financials and market news.Sep-22-21 11:32PM. Synlogic Announces Pricing of Public Offering of Common Stock. (PR Newswire) Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory …With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Instagram:https://instagram. fidelity chartscamping world holdingsspy technical analysisinstant pet insurance no waiting period Analyst Keay Nakae of Chardan Capital reiterated a Buy rating on Synlogic (SYBX – Research Report), with a price target of $35.00. Keay Nakae’s Buy rating for Synlogic is rooted in several ... tslq etfcharge stock Nov 30, 2023 · Grading Synlogic Inc Stock. Before you choose to buy, sell or hold Synlogic Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement. option trading best platform The upgrade of Synlogic, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term ...Find out all the key statistics for Synlogic, Inc. (SYBX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.2.46. +0.16. +6.96%. Get Synlogic Inc (SYBX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.